Animal rights activist who targeted Novartis convicted in U.K.; Adcock admits 'extreme pressure' on profits; Recipharm plans share sale in Stockholm;

@FiercePharma: Statins and muscle aches are unrelated. Story | Follow @FiercePharma

@TracyStaton: FiercePharma's best-read weekend news: Gilead's hot-selling Sovaldi draws more patent attacks. Article | Follow @TracyStaton

@EricPFierce: New purification plant is part of Novo Nordisk's $3.7B R&D push. News | Follow @EricPFierce

> The U.K. animal rights activist who targeted former Novartis ($NVS) Chairman and CEO Daniel Vasella was convicted of conspiracy to commit blackmail. Report

> South Africa's Adcock Ingram said its quarterly profits are under "extreme pressure" as consumers cut back on medications. Report

> The Swedish drugmaker Recipharm plans to sell shares in Stockholm, hoping to raise up to 898 million crowns, or about $142 million. Report

> Germany-based Bayer says it's looking at expanding further in emerging markets, particularly in Africa. Report

> Sir Andrew Dillon, CEO of the U.K.'s cost-effectiveness agency, called for more data transparency in pharma to improve the industry's relationship with healthcare providers. Report

Medical Device News

@FierceMedDev: Here's our latest FierceDiagnostics, with news on concussion biomarkers, autism tests and more. Newsletter | Follow @FierceMedDev

@MarkHFierce: A European VC firm is raising $ for a new fund that will target, in part, Dx and device companies. Story | Follow @MarkHFierce

@MichaelGFierce: NASA tech makes space-age microcapsules for cancer drug delivery. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Good news for chocolate lovers: Bacteria in the gut can eat up cocoa and turn it into compounds that help the heart. Article | Follow @EmilyWFierce

> C.R. Bard enrolls first patient in a new U.S. clinical trial of its drug-coated balloon. News

> Augmedix grabs $3.2M for Google Glass-enabled medical records physician tool. More

> Flagging Smiths Medical, soaring pound weigh down Smiths Group earnings. Story

Biotech News

@FierceBiotech: Novo touts a PhIII hemophilia win as it chases Biogen, Bayer. Story | Follow @FierceBiotech

@JohnCFierce: Bristol-Myers partner Alder Bio looking for $115M IPO haul - clazakizumab and migraine drug ALD403. More | Follow @JohnCFierce

@DamianFierce: Proteon sets out on its own after Novartis waves off a $550M deal. News | Follow @DamianFierce

@GalenMoore: Exact Sciences' at-home test for colon cancer is nearly as effective as a colonoscopy. Read more at Bloomberg | Follow @GalenMoore

> The FDA vs. the flash mob: Hard questions as parents demand unproven drugs. More

> A renal cancer study fails and stock plunges, but Bionomics stays upbeat. Story

Drug Delivery News

> MedImmune inks licensing deal with Bioasis for brain delivery platform. News

> GenSpera enrolls brain cancer mid-stage trial with 'grenade' delivery. Story

> NASA tech makes space-age microcapsules for cancer drug delivery. Story

> Harvard scientists fold DNA to make cages for drug delivery. Article

> CeloNova wins a U.S. exemption trial for its nano-coated stent. News

> Oral drugs derived from snail venom could offer less invasive pain management. Brief

Diagnostics News

> Waters Corp. will help develop a blood-based biomarker test to predict the risk of premature birth. Story

> SynapDx and the Broad Institute link to use next-gen sequencing for better autism tests. News

> Quanterix diagnostic spotted a key concussion biomarker in blood. Article

> Is diagnostics maker Corgenix looking to sell itself? Story

> For 2014, Trovagene plots multiple ways to expand the reach of its Dx cancer tech. Story

> Federal funding drops are forcing layoffs at the Broad Institute's genome sequencing arm. Brief

Pharma Marketing News

> They're no Coca-Cola, but top biopharma brands Pfizer, Biogen and Merck still worth billions. Report

> Roche's Perjeta proves a fast fave with cancer docs, but Kadcyla's a speed racer. Story

> McKinsey's four drug launch flavors: Good, bad, ugly and misguided. Story

> Pfizer's impressive Prevnar data isn't enough to win billions in adult sales. Analysis

> For once, the FDA writes up pharma for a simple Facebook violation. News

> Probe finds Novartis not guilty of 'undue influence' at Canadian university eye clinic. Brief

And Finally... A measles outbreak in New York City may have been spread by medical workers. Report

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.